Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic implications of oral hypoglycaemic therapy on the enteroinsular axis in type 2 diabetes
2005-004748-30Phase 4Completed
- Sponsor
- Royal Victoria Regional Health Centre
- Start
- Feb 2006
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of Glucagon-like peptide 1, metformin and nateglinide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Royal Victoria Regional Health Centre. Primary endpoints: Plasma glucose, Plasma insulin and 4 more. Started Feb 2006; status: completed.
02
Drugs
Glucagon-like peptide 1metforminnateglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2005-004748-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004748-30.